Wound Healing Research

TB-4's wound healing properties represent the most extensive body of research:

• Malinda et al. (1999): Published in the Journal of Investigative Dermatology, this study demonstrated that TB-4 accelerated dermal wound healing in aged mice, establishing the foundational evidence for TB-4's wound repair properties
• Philp et al. (2004): Showed TB-4 promoted corneal wound healing through increased cell migration and reduced inflammation, leading to the clinical development program for RGN-259
• Sosne et al. (2015): Phase II clinical trial of topical TB-4 (RGN-259) for dry eye and corneal wound healing showed statistically significant improvement in corneal healing endpoints

Cardiac Research

TB-4's cardioprotective properties have been studied extensively:

• Bock-Marquette et al. (2004): Published in Nature, this landmark study showed TB-4 promoted cardiac cell survival and reduced scar size after myocardial infarction in mice
• Smart et al. (2007): Research at King's College London demonstrated TB-4 activated epicardial progenitor cells, cells that can differentiate into new heart cells, offering a pathway to cardiac regeneration
• NIHR-funded research: Ongoing research continues to explore TB-4's potential for cardiac repair after heart attack and in heart failure

Neurological Research

• Xiong et al. (2012): Demonstrated TB-4 improved functional recovery after traumatic brain injury in rats by promoting neural stem cell proliferation and reducing neuroinflammation
• Morris et al. (2010): Showed TB-4 promoted remyelination in multiple sclerosis models by supporting oligodendrocyte differentiation

Hair Growth Research

• Philp et al. (2004): Published in PNAS, showed TB-4 promoted hair growth in mice through stem cell activation in hair follicles. This remains the foundational study for TB-4 hair growth applications

Equine/Veterinary Evidence

TB-4 (marketed as TB-500 in veterinary contexts) has been used extensively in equine sports medicine for tendon and ligament injuries. While formal controlled trials are limited, veterinary practitioners consistently report improved tendon healing quality, reduced re-injury rates, and faster return to competition in horses treated with TB-4 .

Research Limitations

• Most evidence is preclinical (animal models and cell studies)
• Only corneal healing has reached Phase II clinical trials in humans
• No large-scale randomized controlled trials for systemic TB-4 use in humans
• Optimal dosing for different conditions in humans is not established through clinical trials
• Long-term safety data from controlled studies is limited

Frequently Asked Questions

Is TB-4 well-studied?

TB-4 has an extensive preclinical evidence base with hundreds of published studies. However, human clinical data is limited compared to FDA-approved drugs. The biological mechanisms are well-characterized, and veterinary real-world evidence supports its use.

Are any TB-4 clinical trials ongoing?

RegeneRx Biopharmaceuticals continues to advance RGN-259 (topical TB-4) through clinical development for ophthalmological applications. Broader clinical development for systemic uses faces the challenge of funding for non-patentable natural peptides.

How does TB-4's evidence compare to BPC-157?

Both peptides have extensive preclinical data. TB-4 has the advantage of a published Phase II clinical trial (corneal healing) and the Nature publication on cardiac effects. BPC-157 has more breadth across GI conditions in preclinical models but no clinical trial publications. Neither has robust human clinical trial data for systemic use.